Scientific Evidence

Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomized controlled trials

Jan 2023

Major depressive disorders are prevalent conditions with limited treatment response and remission. Pharmacogenomics tests including CYP2D6 and CYP2C19 genomic variants provide the most reliable actionable approach to guide choice and dosing of antidepressants in major depression to improve outcomes.

Author: Arnone D, et al.

Publication: Neuroscience & Behavioral Reviews

Prediction of progression in Barrett’s esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies

Dec 2022

Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.

Author: Iyer PG, et al.

Publication: Clinical Gastroenterology and Hepatology

Spatialomics delivered to the clinic for improved health outcomes in Barrett’s esophagus

Dec 2022

The spatialomics approach of TissueCypher brings precision pathology to the clinic for more personalized care of patients with BE to improve outcomes.

Author: Munroe C, et al.

Publication: The Journal of Precision Medicine

Prediction of progression in Barrett’s esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies

Dec 2022

Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.

Author: Iyer PG, et al.

Publication: Clinical Gastroenterology and Hepatology

The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms a clinicopathologic-only nomogram at identifying patients who can forego sentinel lymph node biopsy

Nov 2022

Comparison of the i31-GEP for SLNB to the MIA nomogram in patients with T1-T2 tumors with complete data (n=582). The precision of each tool to identify patients with <5% SLN positivity risk was analyzed using 95% confidence intervals.

Author: Zakria D, et al.

Publication: SKIN: Journal of Cutaneous Melanoma

A prospective, multi-center clinical utility study demonstrates that the 40-gene expression profile (40-GEP) test impacts clinical management for medicare-eligible patients with high-risk cutaneous squamous cell carcinoma (cSCC)

Nov 2022

The incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) in the Medicare population are rapidly increasing. The current national guidelines are broad and the available staging systems for stratification are inadequate to accurately guide patient management. 

Author: Saleeby E, et al.

Publication: Skin

The integrated 31-gene expression profile test (i31-GEP) for cutaneous melanoma outperforms the CP-GEP at identifying patients who can forego sentinel lymph node biopsy when applying NCCN guidelines

Nov 2022

Study compared the i31-GEP for SLNB with the CP-GEP to identify patients who can safely forego SLNB.

Author: Glazer A, et al.

Publication: SKIN: Journal of Cutaneous Melanoma

Improving patient selection for adjuvant therapy: considerations for the role of the 31-gene expression profile test

Oct 2022

Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.

Author: Ahmed K, et al.

Publication: Poster, presented at the Society for Melanoma Research Conference, Edinburgh Scotland, October 17-20 2022

Independent validation of TissueCypher to predict progression in community-based Barrett’s esophagus with low grade dysplasia: analysis in a completed prospective study (podium presentation at UEG 2020 annual meeting OP017)

Oct 2022

TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review of LGD as advocated by all guidelines.

Author: Frei NF, et al.

Publication: United European Gastroenterology Journal

An objective spatialomics test standardizes management decisions with potential to improve outcomes for Barrett’s esophagus patients

Oct 2022

This study evaluated the impact that variability in pathologic diagnosis has on patient care and shows how TissueCypher can aid in consistency of BE management.

Author: Frei NF, et al.

Publication: Podium presentation (S386) at ACG 2022, Charlotte

Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials

Sep 2022

IDgenetix-guided therapy demonstrated the most significant efficacy improvement of all​. IDgenetix was 2.65 times more likely to achieve remission vs. control, and had the highest risk ratio of the 4 RCTs with positive outcomes.

Author: Brown L, et al.

Publication: Clinical Pharmacology & Therapeutics

Real-world evidence shows clinicians appropriately use the prognostic 40-gene expression profile (40-GEP) test for high-risk cutaneous squamous cell carcinoma (cSCC) patients

Sep 2022

Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. 

Author: Hooper PB, et al.

Publication: Cancer Investigation